April 29 () - Pfizer said on Wednesday its drug Elrexfio met the main goal in ‌a late-stage trial that tested the blood ...

PHILADELPHIA -- Pfizer and BioNTech said Tuesday they have submitted Covid-19 vaccine data on children ages 5 to 11 to the US Food and Drug Administration for initial review, but are not yet seeking ...

Pfizer (PFE) stock is in focus as a trial for the company's Elrexfio multiple myeloma drug hit the main goal with patients on ...

Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...

NEW YORK, N.Y. — Pfizer and BioNTech announced Friday that they’re submitting new data to the Food and Drug Administration (FDA) that shows their COVID-19 vaccine can be stored at higher temperatures, ...

Pfizer and Astellas have received the US Food and Drug Administration (FDA) acceptance for priority review of their ...

Pfizer on Monday announced it submitted data to the Food and Drug Administration regarding the results of Phase 1 trials for a potential COVID-19 vaccine booster shot. In a press release, Pfizer said ...

The FDA announced efforts to make clinical trials more efficient, starting by reviewing data in real time from trials ...

NEW YORK -- A course of pills developed by Pfizer can slash the risk of being hospitalized or dying from COVID-19 by 89% if taken within three days of developing symptoms, according to results ...

Pfizer highlighted the performance of a weight-loss drug it acquired in last year's deal to buy Metsera. Pfizer's stock closed 3% lower on Tuesday after investors were disappointed by limited midstage ...